Last reviewed · How we verify
Anti-CD25 mAb
Anti-CD25 monoclonal antibody binds to the IL-2 receptor alpha chain (CD25) on activated T cells, depleting or inhibiting regulatory T cells and activated effector T cells.
Anti-CD25 monoclonal antibody binds to the IL-2 receptor alpha chain (CD25) on activated T cells, depleting or inhibiting regulatory T cells and activated effector T cells. Used for Hematologic malignancies (lymphomas, leukemias), Solid tumors (as immunomodulatory agent in combination regimens).
At a glance
| Generic name | Anti-CD25 mAb |
|---|---|
| Also known as | Basiliximab |
| Sponsor | Peking University People's Hospital |
| Drug class | Monoclonal antibody; immunomodulator |
| Target | CD25 (IL-2 receptor alpha chain) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Immunology |
| Phase | Phase 3 |
Mechanism of action
CD25 is the alpha subunit of the high-affinity IL-2 receptor, predominantly expressed on regulatory T cells (Tregs) and activated T lymphocytes. By targeting CD25, this antibody can deplete Tregs to enhance anti-tumor immunity or modulate T cell activation in autoimmune/inflammatory conditions. The mechanism allows selective immunomodulation depending on the disease context and dosing strategy.
Approved indications
- Hematologic malignancies (lymphomas, leukemias)
- Solid tumors (as immunomodulatory agent in combination regimens)
Common side effects
- Cytokine release syndrome
- Infection (opportunistic and bacterial)
- Infusion reactions
- Lymphopenia
- Immune-related adverse events
Key clinical trials
- IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed (PHASE3)
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (PHASE1, PHASE2)
- Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (PHASE2)
- REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy (PHASE1)
- Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study (NA)
- Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model (PHASE2)
- Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study (PHASE2)
- Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD25 mAb CI brief — competitive landscape report
- Anti-CD25 mAb updates RSS · CI watch RSS
- Peking University People's Hospital portfolio CI